Publication: SEOM Clinical Guideline of management of soft-tissue sarcoma (2020).
dc.contributor.author | de Juan Ferré, A | |
dc.contributor.author | Álvarez Álvarez, R | |
dc.contributor.author | Casado Herráez, A | |
dc.contributor.author | Cruz Jurado, J | |
dc.contributor.author | Estival González, A | |
dc.contributor.author | Martín-Broto, J | |
dc.contributor.author | Martínez Marín, V | |
dc.contributor.author | Moreno Vega, A | |
dc.contributor.author | Sebio García, A | |
dc.contributor.author | Valverde Morales, C | |
dc.date.accessioned | 2023-02-09T10:39:18Z | |
dc.date.available | 2023-02-09T10:39:18Z | |
dc.date.issued | 2021-01-06 | |
dc.description.abstract | Soft-tissue sarcomas constitute an uncommon and heterogeneous group of tumors of mesenchymal origin. Diagnosis, treatment, and management should be performed by an expert multidisciplinary team. MRI/CT of the primary tumor and biopsy is mandatory before any treatment. Wide surgical resection with tumor-free tissue margin is the mainstay for localized disease. Radiotherapy is indicated in large, deep, high-grade tumors, or after marginal resection not suitable for re-excision. Perioperative chemotherapy should be discussed for high-risk sarcomas of the extremities and trunk-wall. In the case of oligometastatic disease, patients should be considered for local therapies. First-line treatment with anthracyclines (or in combination with ifosfamide) is the treatment of choice. Other drugs have shown activity in second-line therapy and in specific histological subtypes but options are limited and thus, a clinical trial should always be discussed. | |
dc.identifier.doi | 10.1007/s12094-020-02534-0 | |
dc.identifier.essn | 1699-3055 | |
dc.identifier.pmc | PMC8057970 | |
dc.identifier.pmid | 33405052 | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057970/pdf | |
dc.identifier.unpaywallURL | https://link.springer.com/content/pdf/10.1007/s12094-020-02534-0.pdf | |
dc.identifier.uri | http://hdl.handle.net/10668/16929 | |
dc.issue.number | 5 | |
dc.journal.title | Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico | |
dc.journal.titleabbreviation | Clin Transl Oncol | |
dc.language.iso | en | |
dc.organization | Hospital Universitario Reina Sofía | |
dc.organization | Hospital Universitario Virgen del Rocío | |
dc.page.number | 922-930 | |
dc.pubmedtype | Journal Article | |
dc.pubmedtype | Practice Guideline | |
dc.rights | Attribution 4.0 International | |
dc.rights.accessRights | open access | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject | Guidelines | |
dc.subject | Sarcoma | |
dc.subject | Soft-tissue tumors | |
dc.subject | Uncommon tumors | |
dc.subject.mesh | Anthracyclines | |
dc.subject.mesh | Antineoplastic Agents | |
dc.subject.mesh | Checklist | |
dc.subject.mesh | Chemotherapy, Adjuvant | |
dc.subject.mesh | Dermatofibrosarcoma | |
dc.subject.mesh | Female | |
dc.subject.mesh | Fibromatosis, Aggressive | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Magnetic Resonance Imaging | |
dc.subject.mesh | Male | |
dc.subject.mesh | Medical Oncology | |
dc.subject.mesh | Neoadjuvant Therapy | |
dc.subject.mesh | Radiotherapy | |
dc.subject.mesh | Retroperitoneal Neoplasms | |
dc.subject.mesh | Sarcoma | |
dc.subject.mesh | Societies, Medical | |
dc.subject.mesh | Soft Tissue Neoplasms | |
dc.subject.mesh | Solitary Fibrous Tumors | |
dc.subject.mesh | Spain | |
dc.subject.mesh | Tomography, X-Ray Computed | |
dc.subject.mesh | Uterine Neoplasms | |
dc.title | SEOM Clinical Guideline of management of soft-tissue sarcoma (2020). | |
dc.type | research article | |
dc.type.hasVersion | VoR | |
dc.volume.number | 23 | |
dspace.entity.type | Publication |
Files
Original bundle
1 - 1 of 1